登入選單
返回Google圖書搜尋
其他書名
Lipid Disorders
出版CSF Medical Communications, 2004-09
ISBN19050644549781905064458
URLhttp://books.google.com.hk/books?id=PGbyAAAACAAJ&hl=&source=gbs_api
註釋Drugs in Context is an independent, peer reviewed and practice orientated review of all the significant data on a specific drug, placed in the context of the disease and clinical practice setting. Simvastatin; - the Scandinavian Simvastatin Survival Study (4S) and the Heart Protection Study (HPS) - confirmed reductions in CHD events as well as all-cause mortality and showed no increase in non-cardiovascular mortality or cancer in the treatment groups. Disease Overview: Raised cholesterol, in particular low density lipoprotein cholesterol (LDL-C), appears to be a pivotal risk factor in the development of coronary heart disease (CHD). Drug Review: In general, simvastatin elicited superior improvements in HDL-C, compared with atorvastatin, fluvastatin and pravastatin and was associated with similar or greater reductions in LDL-C, depending on the comparator statin. Improving Practice: The burden of cardiovascular disease in the UK is large and is likely to increase as the population ages. At current rates, nearly half the population will die from a cardiovascular cause and so the problem impacts on all healthcare professionals.